دورية أكاديمية
887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial
| العنوان: | 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial |
|---|---|
| المؤلفون: | Baudin, E., Walter, Thomas, Beron, A., Smith, D., Hadoux, J., Lachachi, C., Taieb, D., Ansquer, C., Dierickx, L.O., de Mestier Du Bourg, L., Deshayes, E., Quak, E., Dahan, L., Guimbaud, R., Touchefeu, Y., Haissaguerre, M., Do Cao, C., Lombard Bohas, C., Attard, M., Foulon, S. |
| المساهمون: | Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hôpital Edouard Herriot CHU - HCL |
| المصدر: | ISSN: 0923-7534. |
| بيانات النشر: | HAL CCSD Elsevier |
| سنة النشر: | 2022 |
| المجموعة: | HAL Lyon 1 (University Claude Bernard Lyon 1) |
| مصطلحات موضوعية: | [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology |
| الوصف: | International audience |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | hal-04490313; https://hal.science/hal-04490313Test |
| DOI: | 10.1016/j.annonc.2022.07.1013 |
| الإتاحة: | https://doi.org/10.1016/j.annonc.2022.07.1013Test https://hal.science/hal-04490313Test |
| حقوق: | http://creativecommons.org/licenses/by-nc-ndTest/ |
| رقم الانضمام: | edsbas.C2AE2156 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2022.07.1013 |
|---|